Therapeutic Potential of Fingolimod on Psychological Symptoms and Cognitive Function in Neuropsychiatric and Neurological Disorders

• Published in: Neurochemical research 2024-10, Vol.49 (10), p.2668-2681
• Main Authors: Rahmati-Dehkordi, Fatemeh, Khanifar, Hadi, Najari, Nazanin, Tamtaji, Zeinab, Talebi Taheri, Abdolkarim, Aschner, Michael, Shafiee Ardestani, Mehdi, Mirzaei, Hamed, Dadgostar, Ehsan, Nabavizadeh, Fatemeh, Tamtaji, Omid Reza
• Format: Article
• Language: English
• Subjects: Animals; Apoptosis; Autophagy; Biochemistry; Biomedical and Life Sciences; Biomedicine; Cell Biology; Cognition - drug effects; Cognition - physiology; Cognitive ability; Excitability; Excitation spectra; Fingolimod Hydrochloride - pharmacology; Fingolimod Hydrochloride - therapeutic use; FTY720; Global health; Humans; Immune system; Immunological memory; Medical innovations; Mental disorders; Mental Disorders - drug therapy; Mental Disorders - metabolism; Multiple sclerosis; Nervous System Diseases - drug therapy; Nervous System Diseases - metabolism; Neurochemistry; Neurological diseases; Neurological disorders; Neurology; Neuromodulation; Neuroprotection; Neuroprotective Agents - pharmacology; Neuroprotective Agents - therapeutic use; Neurosciences; Oxidative stress; Oxidative Stress - drug effects; Plastic foam; Public health; Review; Sphingosine 1 Phosphate Receptor Modulators - pharmacology; Sphingosine 1 Phosphate Receptor Modulators - therapeutic use; Sphingosine 1-phosphate; Synaptic plasticity; Synaptic transmission; γ-Aminobutyric acid
• ISSN: 0364-3190; 1573-6903; 1573-6903
• DOI: 10.1007/s11064-024-04199-5

Neuropsychiatric and neurological disorders pose a significant global health burden, highlighting the need for innovative therapeutic approaches. Fingolimod (FTY720), a common drug to treat multiple sclerosis, has shown promising efficacy against various neuropsychiatric and neurological disorders. Fingolimod exerts its neuroprotective effects by targeting multiple cellular and molecular processes, such as apoptosis, oxidative stress, neuroinflammation, and autophagy. By modulating Sphingosine-1-Phosphate Receptor activity, a key regulator of immune cell trafficking and neuronal function, it also affects synaptic activity and strengthens memory formation. In the hippocampus, fingolimod decreases glutamate levels and increases GABA levels, suggesting a potential role in modulating synaptic transmission and neuronal excitability. Taken together, fingolimod has emerged as a promising neuroprotective agent for neuropsychiatric and neurological disorders. Its broad spectrum of cellular and molecular effects, including the modulation of apoptosis, oxidative stress, neuroinflammation, autophagy, and synaptic plasticity, provides a comprehensive therapeutic approach for these debilitating conditions. Further research is warranted to fully elucidate the mechanisms of action of fingolimod and optimize its use in the treatment of neuropsychiatric and neurological disorders.